| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
PKA I PKA II PDE3A 47.6 μM (Ki) PDE10 GAF domain 50 μM (EC50)
|
|---|---|
| ln Vitro |
The irritating diastereomer of adenosine cyclic 3',5'-phosphorothioate, or Sp-cAMPS sodium salt, stimulates hepatocytes in a manner similar to that induced by glucagon. The rise in Ca2+ levels induced by glucagon can be mimicked by the sodium salt Sp-cAMPS [4].
|
| ln Vivo |
Direct injection of Sp-cAMPS (1 µg/µL) sodium salt into the prefrontal cortex of chronic alcohol consumption (CAC) mice either dramatically improved the working memory performance of withdrawn animals or negatively impacted the performance of aquatic animals [5].
|
| References |
[1]. Su H Hung, et al. A new nonhydrolyzable reactive cAMP analog, (Sp)-adenosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase. Bioorg Chem. 2002 Feb;30(1):16-31.
[2]. L Y Wang, et al. Regulation of kainate receptors by cAMP-dependent protein kinase and phosphatases. Science. 1991 Sep 6;253(5024):1132-5. [3]. Ronald Jäger, et al. Activation of PDE10 and PDE11 phosphodiesterases. J Biol Chem. 2012 Jan 6;287(2):1210-9. [4]. P A Connelly,et al. A study of the mechanism of glucagon-induced protein phosphorylation in isolated rat hepatocytes using (Sp)-cAMPS and (Rp)-cAMPS, the stimulatory and inhibitory diastereomers of adenosine cyclic 3',5'-phosphorothioate. J Biol Chem. 1987 Mar 25;262(9):4324-32. [5]. G Dominguez, et al. Rescuing prefrontal cAMP-CREB pathway reverses working memory deficits during withdrawal from prolonged alcohol exposure. Brain Struct Funct. 2016 Mar;221(2):865-77. |
| Molecular Formula |
C10H11N5NAO5PS
|
|---|---|
| Molecular Weight |
367.25
|
| CAS # |
142439-95-0
|
| Related CAS # |
Rp-cAMPS triethylammonium salt;151837-09-1;Rp-cAMPS sodium salt;142439-94-9;Rp-cAMPS;73208-40-9;Sp-cAMPS;71774-13-5;Sp-cAMPS triethylamine;93602-66-5
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
C1[C@@H]2[C@H]([C@H]([C@H](N3C=NC4=C(N)N=CN=C43)O2)O)O[P@](=S)([O-])O1.[Na+]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (272.29 mM)
H2O: 86.67 mg/mL (236.00 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (136.15 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7229 mL | 13.6147 mL | 27.2294 mL | |
| 5 mM | 0.5446 mL | 2.7229 mL | 5.4459 mL | |
| 10 mM | 0.2723 mL | 1.3615 mL | 2.7229 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
